SpyGlass Pharma, an Aliso Viejo, CA-based ophthalmic therapeutics company, raised $90M in Series C funding.
The round was led by RA Capital Management alongside existing investors New Enterprise Associates and Vensana Capital, as well as new investors Samsara BioCapital and Vertex Ventures HC.
The company intends to use the funds to support multiple US clinical trials of its drug delivery platform.
Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman, and led by Patrick Mooney, CEO, SpyGlass Pharma focuses on the development of an IOL-mounted, controlled release drug delivery platform capable of delivering multiple years of therapy. The technology was originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine and spun off campus post Series A funding from New Enterprise Associates.
